Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2737-2741

  Platzer, Peter ^a   Herzog, Wolfgang ^a   Thalhammer, Therese ^a   Hamilton, Gerhard ^a,b   Haberl, Ines ^a   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

DU 145; Metabolism; PC 3; Prostate; Topotecan

Indexed keywords

ANTINEOPLASTIC ALKALOID; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; TOPOTECAN;

ARTICLE; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL LINE;

BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOENZYMES; KINETICS; MALE; PROSTATIC NEOPLASMS; TIME FACTORS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0031810797     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54: 461-470, 1970.
2. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Pharmacol 56: 95-101, 1972.
3. Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry OS: Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
4. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating M, Estey EH: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81: 1146-1151, 1993.
5. Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJC: An overview of the clinical pharmacology oftopotecan. Semin Oncol 24 (1, Suppl 5): S5-12-S5-18, 1997.
6. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32: 921-926, 1996.
7. Caserini C, Pratesi G, Tortoreto M, Bedogne B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F: Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin Cancer Res 3: 955-961, 1997.
8. Sinha BK: Topoisomerase inhibitors - a review of their therapeutic potential in cancer. Drugs 49: 11-19, 1995.
9. Herben VMM, ten Bokkel Huinik WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31: 85-102, 1996.
10. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ: Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest. New Drugs 13: 235-40 1995.
11. Krishan A, Fitz CM, Andritsch I: Drug retention, efflux, and resistance in tumor cells. Cytometry 29: 279-285, 1997.
12. Rosing H, Herben VMM, van Gortel-van Zomeren DM, Hop E, Kettenes van den Bosch JJ, ten Bokkel Huinink WW, Beijnen JH: Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 39: 498-504, 1997.
13. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB: Clinical pharmacodynamics of continuous topotecan infusion in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12: 1946, 1994.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
15. Ohmura T, Sato R: The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239: 2370-2378, 1964.
16. Jaeger W, Benet LZ, Bornheim LM: Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26: 275-284, 1996.
17. Bjelfman C, Finnstrom N, Soderstrom T, Smith G, Wolf CR, Rane A: Expression of cytochrome P450 enzymes in the prostate as assessed by multiplex RT-PCR. ISSX Proc 11: 87, 1997.
18. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G: Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urology 150: 1544-1547, 1993.
19. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M, Kuwano M: A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57: 5475-5479, 1997.
20. Chu XY, Kato Y, Sugiyama Y: Multiplicity of biliary excretion mechanism for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57: 1934-1938, 1997.